Exhibit
10.1


 





Execution
Version

 


SECURITIES
PURCHASE AGREEMENT


 


This
Securities Purchase Agreement (this “Agreement”) is dated as of April 8, 2021 (the “Effective Date”),
between Todos Medical Ltd., a corporation organized under the laws of Israel (the “Company”), and _______ (the
“Purchaser”).


 


WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act”), and/or Rule 506 promulgated thereunder, the Company desires to issue and
sell to the Purchasers, and the Purchaser desires to purchase from the Company, securities of the Company, as more fully described
in this Agreement (the “Offering”).


 


NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:


 


ARTICLE
I


DEFINITIONS


 


1.1
Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise
defined herein have the meanings given to such terms in the Note (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1:


 


“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.9.


 


“Action”
shall have the meaning ascribed to such term in Section 3.1(j).


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.


 


“Board
of Directors” means the board of directors of the Company.


 


“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.


 


“Buy-In”
has the meaning set forth in Section 4.2(c).


 


“Closing”
or “Closings” shall have the meaning ascribed to such term in Section 2.1.


 


“Closing
Date” shall mean the Initial Closing Date or Second Closing Date, as context requires.


 


“Closing
Statement” means the Closing Statement in the form of Annex A attached hereto.


 




    	 



    	 



    

 


“Commission”
means the United States Securities and Exchange Commission.


 


“Common
Stock” means the Ordinary Shares of the Company, par value NIS 0.01 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed.


 


“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common
Stock.


 


“Company”
means Todos Medical Ltd.


 


“Conversion
Price” shall have the meaning ascribed to such term in the Note.


 


“Conversion
Shares” means the shares of Common Stock issued and issuable upon conversion or redemption of the Note and issued and
issuable in lieu of the cash payment of interest on the Note in accordance with the terms of the Note.


 


“Disqualifying
Event” shall have the meaning ascribed to such term in Section 3.1(ff).


 


“Effective
Amount” shall have the meaning ascribed to such term in the preamble.


 


“Environmental
Laws” shall have the meaning ascribed to such term in Section 3.1(q).


 


“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(q).


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers, directors or consultants
of the Company pursuant to any stock or option plan or agreement duly adopted for such purpose by the Board of Directors or a
majority of the members of a committee of non-employee directors established for such purpose up to the amounts on the terms set
forth on Schedule 3.1(g) consistent with past practices, (b) securities upon the exercise, exchange or conversion of the
Note or Warrants issued hereunder and/or other securities, options, warrants, convertible securities or other rights to acquire,
exercisable or exchangeable for or convertible into, shares of Common Stock, in each case that are issued and outstanding on the
date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise, exchange or conversion price of such securities and which securities and the principal
terms thereof are set forth on Schedule 3.1(g) or described in the SEC Reports, (c) securities issued pursuant to acquisitions
of companies, assets or intellectual property (or licensing of assets or intellectual property) or strategic transactions approved
by a majority of the disinterested directors of the Company, if any, provided that any such issuance shall only be to a Person
which is, itself or through its subsidiaries, an operating company, a university or other non-financial institution and in which
the Company receives benefits in addition to the investment of funds but shall not include a transaction in which the Company
is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities,
(d) securities issued or issuable in exchange for consideration other than cash in connection with any other transaction that
is not for the primary purpose of financing the Company’s business, but shall not include a transaction in which the Company
is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities,
or (e) securities issued or issuable to the Purchasers or their assigns pursuant to this Agreement, the Note, the Warrants or
other Transaction Documents, or upon conversion or exchange of any such securities.


 




    	2



    	 



    

 


“FDA”
has the meaning set forth in Section 3.1(nn).


 


“FDCA”
has the meaning set forth in Section 3.1(nn).


 


“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).


 


“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(gg).


 


“Initial
Closing” shall have the meaning ascribed to such term in Section 2.1.


 


“Initial
Closing Date” shall have the meaning ascribed to such term in Section 2.1(a).


 


“Initial
Closing Payment” shall have the meaning ascribed to such term in Section 2.1(a).


 


“Initial
Note” means the convertible promissory note described in Section 2.2(a)(iii), substantially in the form attached hereto
as Exhibit A.


 


“Initial
Securities” shall have the meaning ascribed to such term in Section 2.1(a).


 


“Initial
Subscription Amount” shall have the meaning ascribed to such term in Section 2.1(a).


 


“Initial
Warrant” means the Common Stock purchase warrant described in Section 2.2(a)(iii), substantially in the form attached
hereto as Exhibit B.


 


“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(o).


 


“Legend
Removal Date” shall have the meaning ascribed to such term in Section 4.2(c).


 


“Liens”
means a lien, charge, pledge. security interest, encumbrance, right of first refusal, preemptive right or other restriction.


 




    	3



    	 



    

 


“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).


 


“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(m).


 


“Maximum
Rate” shall have the meaning ascribed to such term in Section 5.17.


 


“Money
Laundering Laws” shall have the meaning ascribed to such term in Section 3.1(jj).


 


“New
Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights,
options, or warrants to purchase such equity securities, or notes or securities of any type whatsoever that are, or may become,
convertible or exchangeable into or exercisable for such equity securities.


 


“Note”
means the Initial Note or Second Note, as context requires.


 


“Notice
Termination Time” has the meaning set forth in Section 4.20.


 


“OFAC”
shall have the meaning ascribed to such term in Section 3.1(ll).


 


“OID”
means original issuer discount.


 


“Organizational
Change” has the meaning set forth in Section 4.15.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Pharmaceutical
Product” has the meaning set forth in Section 3.1(nn).


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.


 


“Public
Information Failure” has the meaning set forth in Section 4.5(b).


 


“Public
Information Failure Payments” has the meaning set forth in Section 4.5(b).


 


“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.12.


 


“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).


 


“Required
Minimum” means, as of any date, one hundred fifty percent (150%) of the maximum aggregate number of shares of Common
Stock then potentially issuable in the future pursuant to the Transaction Documents, including Warrant Shares issuable upon exercise
of the Warrants and Conversion Shares issuable upon conversion in full of the Note (including Conversion Shares issuable as payment
of interest on the Note), ignoring any conversion or exercise limits set forth therein.


 




    	4



    	 



    

 


“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.


 


“Second
Closing” shall have the meaning ascribed to such term in Section 2.1.


 


“Second
Closing Date” shall have the meaning ascribed to such term in Section 2.1(b).


 


“Second
Closing Payment” shall have the meaning ascribed to such term in Section 2.1(b).


 


“Second
Note” means the convertible promissory note described in Section 2.2(c)(ii), substantially in the form attached hereto
as Exhibit A.


 


“Second
Securities” shall have the meaning ascribed to such term in Section 2.1(b).


 


“Second
Subscription Amount” shall have the meaning ascribed to such term in Section 2.1(b).


 


“Second
Warrant” means the Common Stock purchase warrant described in Section 2.2(c)(iii), substantially in the form attached
hereto as Exhibit B.


 


“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).


 


“Securities”
means, with respect to the Initial Securities or Second Securities, as context requires, the Commitment Shares, the Note, the
Warrants, the Warrant Shares and the Conversion Shares.


 


“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).


 


“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a) and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.


 


“Trading
Day” means a day on which the principal Trading Market is open for trading.


 




    	5



    	 



    

 


“Trading
Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).


 


“Transaction”
has the meaning set forth in Section 4.20.


 


“Transaction
Documents” means this Agreement, the Note, the Warrants, Transfer Agent Instructions relating to the Securities, all
exhibits and schedules thereto and hereto and thereto, and any other documents or agreements executed in connection with the transactions
contemplated hereunder.


 


“Transfer
Agent” means Worldwide Stock Transfer, LLC, the current transfer agent of the Company with a mailing address of 1 University
Plaza Drive #505, Hackensack, NJ and a facsimile number of (201) 820-2010, and any successor transfer agent of the Company.


 


“Unlegended
Shares” has the meaning set forth in Section 4.2(c).


 


“Variable
Rate Transaction” has the meaning set forth in Section 4.14.


 


“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. New York City time to 4:02 p.m. New York City time); (b) if the Common Stock is not then listed
or quoted for trading on a Trading Market and if prices for the Common Stock are then reported on the OTC Pink (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported;
or (c) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchaser and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.


 


“Warrant”
means the Initial Warrant or Second Warrant, as context requires.


 


“Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.


 


“Yozma”
has the meaning set forth in Section 4.14.


 




    	6



    	 



    

 


ARTICLE
II


PURCHASE
AND SALE


 


2.1
Closings. The Company and Purchaser shall consummate the Offering pursuant to two (2) closings: (i) an initial closing
for the purchase and sale of the Initial Note and the Initial Warrant (the “Initial Closing”) for a subscription
amount equal to Four Million Two Hundred Eighty-Five Thousand Seven Hundred Fourteen Dollars and Twenty-Nine Cents ($4,285,714.29)
(the “Initial Subscription Amount”), and (ii) a second closing whereby Purchaser shall have the option, but
not the obligation, to purchase in its sole discretion the Second Note and Second Warrant (the “Second Closing”),
for a subscription amount of Five Million Two Hundred Eighty-Five Thousand Seven Hundred Fourteen Dollars and Twenty-Nine Cents
($5,285,714.29), (the “Second Subscription Amount”). The Initial Closing and Second Closing are collectively
referred to herein as the “Closings,” and each individually, a “Closing.” The Initial Closing
shall occur on the Effective Date (the “Initial Closing Date”). Upon satisfaction of the applicable conditions
set forth in Sections 2.2 and 2.3, each Closing shall occur at the offices of Nelson Mullins Riley & Scarborough, LLP, 4140
Parklake Avenue, Second Floor, Raleigh, NC 27612, or such other location as the parties shall mutually agree.


 


	 	(a)	Initial
    Closing. The Initial Closing shall occur on the Effective Date (the “Initial Closing Date.” On the
    Initial Closing Date, upon the terms and subject to the conditions set forth herein, the Company hereby agrees to sell, and
    the Purchaser hereby agrees to purchase, the Initial Note and the Initial Warrant, as further described in Section 2.2(a)
    (collectively, the “Initial Securities”), for a purchase price of Three Million Hundred Dollars ($3,000,000.00)
    (the “Initial Closing Payment”); provided, however, that in no event shall the consummation of the transactions
    contemplated in the Initial Closing create any obligation for Purchaser to consummate the transactions contemplated in the
    Second Closing. On the Initial Closing Date, the Company shall deliver to Purchaser each item set forth in Section 2.2(a),
    and Purchaser shall deliver to the Company each item set forth in Section 2.2(b).
	 	 	 
	 	(b)	Second
    Closing. The Second Closing shall occur, if at all, on the date that is ninety (90) days following the date of effectiveness
    of any registration statement filed by the Company under the Exchange Act or the Securities Act with respect to the Initial
    Securities (such date, the “Second Closing Date”). On the Second Closing Date, upon the terms and subject
    to the conditions set forth herein, Purchaser shall have the option, exercisable Purchaser’s sole discretion, to purchase
    the Second Note and the Second Warrant, as further described in Section 2.2(c) (collectively, the “Second Securities”),
    for a purchase price of Three Million Seven Hundred Thousand Dollars ($3,700,000.00) (the “Second Closing Payment”).
    On the Second Closing Date, the Company shall deliver to Purchaser each item set forth in Section 2.2(c), and Purchaser shall
    deliver to the Company each item set forth in Section 2.2(d).


 


2.2
Deliveries.


 


	 	(a)	On
    the Initial Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:


 


	 	(i)	this
    Agreement duly executed by the Company;


 




    	7



    	 



    

 


	 	(ii)	a
    Closing Statement, substantially in the form attached hereto as Annex A, duly executed by the Company, setting forth
    the Flow of Funds with respect to the Initial Closing Payment;
	 	 	 
	 	(iii)	A
    Note, substantially in the form attached hereto as Exhibit A and reasonably satisfactory to Purchaser, in a principal
    amount of Four Million Two Hundred Eighty-Five Thousand Seven Hundred Fourteen Dollars and Twenty-Nine Cents ($4,285,714.29),
    with a thirty percent (30%) OID, registered in the name of the Purchaser (the “Initial Note”); and
	 	 	 
	 	(iv)	a
    Warrant registered in the name of the Purchaser to purchase up to sixteen thousand (16,000,000) shares of Common Stock, with
    an exercise price equal to $0.107415, subject to adjustment therein (the “Initial Warrant”).


 


	 	(b)	On
    the Initial Closing Date, the Purchaser shall deliver or cause to be delivered to the Company the following:


 





	 	(i)	a
    counterpart of this Agreement duly executed by the Purchaser; and
	 	 	 
	 	(ii)	Purchaser’s
    Initial Closing Payment by wire transfer to the account as specified in writing by the Company.


 


	 	(c)	On
    the Second Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:


 


	 	(i)	a
    Closing Statement, substantially in the form attached hereto as Annex A, duly executed by the Company, setting forth
    the Flow of Funds with respect to the Second Closing Payment;
	 	 	 
	 	(ii)	A
    Note, substantially in the form attached hereto as Exhibit A and reasonably satisfactory to Purchaser, in a principal
    amount of Five Million Two Hundred Eighty-Five Thousand Seven Hundred Fourteen Dollars and Twenty-Nine Cents ($5,285,714.29),
    with a thirty percent (30%) OID, registered in the name of the Purchaser (the “Second Note”); and
	 	 	 
	 	(iii)	a
    Warrant registered in the name of the Purchaser to purchase up to sixteen thousand (16,000,000) shares of Common Stock, with
    an exercise price equal to $0.107415, subject to adjustment therein (the “Second Warrant”).


 


	 	(d)	On
    the Second Closing Date, the Purchaser shall deliver or cause to be delivered to the Company, Purchaser’s Second Closing
    Payment by wire transfer to the account specified in writing by the Company.


 




    	8



    	 



    

 


2.3
Closing Conditions.


 


(a)
The obligations of the Company hereunder in connection with each Closing are subject to the following conditions being met:


 


	 	(i)	the
    accuracy in all material respects (determined without regard to any materiality, Material Adverse Effect or other similar
    qualifiers therein) on such Closing Date of the representations and warranties of the Purchaser contained herein;
	 	 	 
	 	(ii)	all
    obligations, covenants and agreements of the Purchaser required to be performed at or prior to such Closing Date shall have
    been performed;
	 	 	 
	 	(iii)	the
    delivery by the Purchaser of the items set forth in Section 2.2(b) and (d) of this Agreement, as the case may be; and


 


(b)
The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met, unless
waived in the sole and absolute discretion of the Purchaser:


 


	 	(i)	the
    accuracy in all respects (determined without regard to any materiality, Material Adverse Effect or other similar qualifiers
    therein) when made and on such Closing Date of the representations and warranties of the Company contained herein;
	 	 	 
	 	(ii)	all
    obligations, covenants and agreements of the Company required to be performed at or prior to such Closing Date shall have
    been performed;
	 	 	 
	 	(iii)	the
    delivery by the Company of the items set forth in Section 2.2(a) and (c), as the case may be, of this Agreement; and
	 	 	 
	 	(iv)	there
    shall have been no Material Adverse Effect with respect to the Company since the date hereof.


 


ARTICLE
III


REPRESENTATIONS
AND WARRANTIES


 


3.1
Representations and Warranties of the Company. Except as set forth in the SEC Reports shall be deemed a part hereof and
shall qualify any representation or otherwise made herein only to the extent of the disclosure contained in the corresponding
section of the SEC Reports, the Company hereby makes the following representations and warranties to each Purchaser as of the
Closing, except where otherwise indicated:


 


(a)
Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company
owns, directly or indirectly, the capital stock or other equity interests of each Subsidiary, in the amounts set forth on Schedule
3.1(a), free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are
validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.
If the Company shall at any time in which the Note remains outstanding have no subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.


 




    	9



    	 



    

 


(b)
Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the
Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse
effect on the Company’s ability to perform in any respect on a timely basis its obligations under any Transaction Document
(any of (i), (ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been instituted in any such
jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.


 


(c)
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of each of the Transaction Documents by the Company and the consummation by it of the transactions
contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action
is required by the Company, the Board of Directors or the Company’s stockholders in connection therewith other than in connection
with the Required Approvals. Each Transaction Document to which it is a party has been (or upon delivery will have been) duly
executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.


 




    	10



    	 



    

 


(d)
No Conflicts. The execution, delivery and performance by the Company of the Transaction Documents and the consummation
by it of the other transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision
of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter
documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others
any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice,
lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company
or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of
any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.


 


(e)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority
or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other
than: (i) the filings required pursuant to Section 4.8, (ii) such consents, waivers, or authorizations as have been obtained before
the initial Closing, (iii) if required, the notice and/or application(s) to each applicable Trading Market for the issuance and
sale of the Securities and the listing or quotation of the Conversion Shares or the Warrant Shares for trading thereon in the
time and manner required thereby, and (iv) the filing of Form D with the Commission and such filings as are required to be made
under applicable state securities laws (collectively, the “Required Approvals”).


 


(f)
Issuance of the Securities. The issuance of the Securities has been duly authorized by all applicable corporate power and
authority, and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued,
fully paid and nonassessable, free and clear of any and all Liens imposed by the Company other than restrictions on transfer provided
for in the Transaction Documents. The Warrant Shares and the Conversion Shares, when issued in accordance with the terms of the
Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents. The Company has reserved the Required Minimum from
its duly authorized capital stock a number of shares of Common Stock for issuance of the Warrant Shares and the Conversion Shares.


 




    	11



    	 



    

 


(g)
Capitalization. The capitalization of the Company immediately prior to the Closing is, in all material respects, as set
forth in the SEC Reports. Except as provided on Schedule 3.1(g), or the SEC Reports, no Person has (i) any right of first
refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents except for such, if any, as will have been validly waived before the Closing and (ii) except pursuant to
the operation of agreements filed as exhibits to the SEC Reports before the date of this Agreement and as set forth on Schedule
3.1(j), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any
right to subscribe for or acquire any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common
Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company to issue shares of Common Stock or other securities to any Person (other than the Purchaser) and will not result in
a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.
All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued
in compliance with all applicable laws (including, without limitation, applicable federal and state securities laws), and none
of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale
of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s
stockholders.


 


(h)
SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under Section 13(a) or 15(d) of the Exchange Act for the two (2) years preceding the date
hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC
Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports
prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects
with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material
respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments. The Company is, and has no reason to believe that it will not in the foreseeable future continue to
be in compliance with all its reporting requirements under the Securities Act and Exchange Act.


 




    	12



    	 



    

 


(i)
Material Changes. Except as provided in Schedule 3.1(i) hereto, since the date of the latest audited financial statements
included in the SEC Reports: (i) there has been no event, occurrence or development that has had or that could reasonably be expected
to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the
Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared, nor has the Board of
Directors of the Company authorized, or made any dividend or distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity
securities or common stock equivalents to any officer, director or Affiliate, except pursuant to existing Company equity incentive
plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for
the issuance of the Securities contemplated by this Agreement and as may otherwise be disclosed herein or in any Schedule hereto,
no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or
exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets
or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this
representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that
this representation is made.


 


(j)
Litigation. Except as described in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any
of their respective assets or properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects
or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or the availability
of the Company to perform its obligations under the Transaction Documents or (ii) could, if there were an unfavorable decision,
have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director,
officer or affiliate thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there
is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or
officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.


 




    	13



    	 



    

 


(k)
Labor Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any
of the employees of the Company which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s
or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company
or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the
Company and its Subsidiaries believe that their relationships with their employees are good. No executive officer of the Company
or any Subsidiary, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract
or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer
does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. To the
Company’s knowledge, the Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.


 


(l)
Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other material agreement or instrument to which it is a party or by which it
or any of its properties is bound (whether or not such default or violation has been waived) and such default or violation has
not been cured, (ii) is in violation of any judgment, decree or order of any court, arbitrator or governmental body or (iii) is
or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in
each of the foregoing cases as may otherwise be disclosed herein or in any Schedule hereto or as could not have or reasonably
be expected to result in a Material Adverse Effect.


 


(m)
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses, except where
the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.


 


(n)
Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property and
good and marketable title in all personal property owned by it that, in each case, is material to the business of the Company
and the Subsidiaries, in each case free and clear of all Liens, except for Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries
and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties
in any material respect. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them
under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.


 




    	14



    	 



    

 


(o)
Patents and Trademarks. (i) The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights as described in the SEC Reports as necessary or material for use in connection with their respective
businesses and which the failure to so have could reasonably be expected to have a Material Adverse Effect (collectively, the
“Intellectual Property Rights”); (ii) neither the Company nor any Subsidiary has received a notice (written
or otherwise) that any of the Intellectual Property Rights violates or infringes upon the rights of any Person; (iii) all such
Intellectual Property Rights are enforceable and to the knowledge of the Company there is no existing infringement by another
Person of any of the Intellectual Property Rights, except where the failure to be so enforceable or for such infringements as
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iv) the Company and
its Subsidiaries have taken all commercially appropriate security measures to protect the secrecy, confidentiality and value of
all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.


 


(p)
Transactions with Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of
the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or
from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or
partner, in each case in excess of One Hundred Twenty Thousand Dollars ($120,000.00) other than for: (i) payment of salary or
consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee
benefits, including stock option agreements under any stock option plan of the Company


 


(q)
Environmental Laws. The Company and its subsidiaries are (i) in compliance with any and all applicable foreign, federal,
state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses
or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in
compliance with all terms and conditions of any such permit, license or approval.


 




    	15



    	 



    

 


(r)
Sarbanes-Oxley; Internal Accounting Controls. The Company is in material compliance with all provisions of the Sarbanes-Oxley
Act of 2002 which are applicable to it as of the Closing Date. The Company and the Subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements
in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.
The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures
as of the end of the period covered by the Company’s most recently filed periodic report under the Exchange Act (such date,
the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the Company’s internal control
over financial reporting (as such term is defined in the Exchange Act) that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial reporting.


 


(s)
Certain Fees. No brokerage, due diligence, finder’s fees or commissions are or will be payable by the Company to
any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to
the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any fees or
with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due
in connection with the transactions contemplated by the Transaction Documents.


 


(t)
Private Placement. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2,
no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchaser
as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the
Trading Market.


 


(u)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act
of 1940, as amended.


 


(v)
Registration Rights. Except as disclosed on Schedule 3.1(v) hereto, no Person has any right to cause the Company
to effect the registration under the Securities Act of any securities of the Company, other than Purchaser or any Affiliate of
Purchaser.


 


(w)
Listing and Maintenance Requirements. (i) The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration, (ii) the Company has not, in the twelve (12) months preceding the date hereof, received notice
from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market and (iii) the Company is, and has no reason to believe that
it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.


 




    	16



    	 



    

 


(x)
Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchaser as a result of
the Purchaser and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including
without limitation as a result of the Company’s issuance of the Securities and the Purchaser’s ownership of the Securities.


 


(y)
Disclosure. Except with respect to (i) the material terms and conditions of the transactions contemplated by the Transaction
Documents and (ii) information given to the Purchaser, if any, which the Company hereby confirms does not constitute material
non-public information, the Company confirms that neither it nor any other Person acting on its behalf has provided the Purchaser
or their agents or counsel with any information that it believes constitutes or might constitute material, nonpublic information.
The Company understands and confirms that the Purchaser will rely on the foregoing representation in effecting transactions in
securities of the Company. All disclosure furnished in writing by or on behalf of the Company to the Purchaser regarding the Company,
its business and the transactions contemplated hereby, including the SEC Reports, is true and correct and does not contain any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during
the twelve (12) months preceding the date of this Agreement do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made and when made, not misleading. The Company acknowledges and agrees that the Purchaser has not made
any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth
in Section 3.2 hereof.


 


(z)
No Integrated Offering. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would
require the registration of any such securities under the Securities Act, or (ii) any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.


 




    	17



    	 



    

 


(aa)
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and each Subsidiary has filed all necessary federal, state and foreign income and franchise
tax returns and has paid or accrued all taxes shown as due thereon, and the Company has no knowledge of a tax deficiency which
has been asserted or threatened against the Company or any Subsidiary. There are no audits pending by any tax or other governmental
authority relating to the payment of taxes by the Company or any subsidiary.


 


(bb)
No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of
the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only
to the Purchaser and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.


 


(cc)
Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on
behalf of the Company, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other
unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose
fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is
in violation of law or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.


 


(dd)
No Disagreements with Accountants and Lawyers; Outstanding SEC Comments. There are no disagreements of any kind presently
existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently
employed by the Company and the Company is or immediately after the Closing Date will be current with respect to any fees owed
to its accountants which could affect the Company’s ability to perform any of its obligations under any of the Transaction
Documents. There are no unresolved comments or inquiries received by the Company or its Affiliates from the Commission which remain
unresolved as of the date hereof.


 


(ee)
Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company acknowledges and agrees that the Purchaser
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by the Purchaser or any of their respective representatives or agents in connection with the Transaction Documents
and the transactions contemplated thereby is merely incidental to the Purchaser’s purchase of the Securities. The Company
further represents to the Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.


 




    	18



    	 



    

 


(ff)
Disqualification. No executive officer, member of the Board of Directors of the Company or shareholder of the Company beneficially
owning more than ten percent (10%) of the Company’s securities is currently subject to a Disqualifying Event. For purposes
of this Agreement, “Disqualifying Event” means any conviction, order, judgment, decree, suspension, expulsion,
event or other matter set out in Rule 506(d)(1)(i) through (viii) of Regulation D that is currently in effect or which occurred
within the periods set out in Rule 506(d)(1)(i) through (viii).


 


(gg)
Solvency. Based on the consolidated financial condition of the Company and Subsidiaries as of the Closing Date, and the
Company’s good faith estimate of the fair market value of its assets, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder: (i) the fair saleable value of the Company’s assets exceeds the
amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to
carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one (1) year from the Closing Date. Schedule 3.1(gg)
discloses, as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for
which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means
(x) any liabilities for borrowed money or amounts owed in excess of One Hundred Thousand Dollars ($100,000.00) in the aggregate
(other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or
similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of One Hundred
Thousand Dollars ($100,000.00) due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any
Subsidiary is in default with respect to any Indebtedness.


 




    	19



    	 



    

 


(hh)
Acknowledgment Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary
notwithstanding, it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company
to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or
“derivative” securities based on securities issued by the Company or to hold the Securities for any specified term,
(ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or “derivative” transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company’s publicly-traded securities, (iii) any Purchaser, and counter-parties in “derivative”
transactions to which any such Purchaser is a party, directly or indirectly, may presently have a “short” position
in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length
counter-party in any “derivative” transaction. The Company further understands and acknowledges that (y) one or more
Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including,
without limitation, during the periods that the value of the Conversion Shares and Warrant Shares deliverable with respect to
Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders’
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges
that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents. The Company acknowledges
that anything to the contrary in the Transaction Documents notwithstanding, Purchaser may sell long any Conversion Shares and
Warrant Shares it anticipates receiving after conversion of any part of the Note or exercise of the Warrants.


 


(ii)
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company.


 


(jj)
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.


 


(kk)
Stock Option Plans. Each stock option and similar security granted by the Company was granted (i) in accordance with the
terms of such any applicable stock option plans and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under any stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial
results or prospects.


 




    	20



    	 



    

 


(ll)
Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director,
officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (“OFAC”).


 


(mm)
Indebtedness and Seniority. As of the date hereof, all Indebtedness and Liens of the Company and the principal terms thereof
are set forth in the SEC Reports. Except as set forth on Schedule 3.1(mm), as of the Closing Date, no Indebtedness or other
equity of the Company is or will be pari passu or senior to the Note in right of payment, whether with respect to interest
or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security interests (which
is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior only as to the property
covered thereby).


 


(nn)
FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is
manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such
product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar
laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising,
record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There
is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal
or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA
or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or
any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its
Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business
and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws,
rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale,
license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA
expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the
Company.


 




    	21



    	 



    

 


(oo)
Survival. The foregoing representations and warranties shall survive the Closing.


 


3.2
Representations and Warranties of the Purchaser. Each Purchaser, as to itself only, hereby represents and warrants as of
the date hereof and as of the Closing Date to the Company as follows:


 


(a)
Organization; Authority. The Purchaser is an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization with full right, corporate, partnership, limited liability company or similar power and
authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out
its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by the Purchaser
of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action on the part of the Purchaser. Each Transaction Document to which it is a party has
been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except: (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.


 


(b)
Own Account. The Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a present view to or for distributing or reselling such Securities or any part thereof in violation of the Securities
Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the
Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting the Purchaser’s
right to sell the Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state
securities laws) in violation of the Securities Act or any applicable state securities law. The Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.


 


(c)
Purchaser Status. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, and on
each date on which it converts any Note or exercises any Warrants it will be either: (i) an “accredited investor”
as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional
buyer” as defined in Rule 144A(a) under the Securities Act. The Purchaser is not required to be registered as a broker-dealer
under Section 15 of the Exchange Act.


 




    	22



    	 



    

 


(d)
Experience of the Purchaser. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.


 


(e)
General Solicitation. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice
or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television
or radio or presented at any seminar or any other general solicitation or general advertisement.


 


The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such
Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transactions contemplated hereby.


 


ARTICLE
IV


OTHER
AGREEMENTS OF THE PARTIES


 


4.1
Underlying Shares. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement
to cover the issuance or resale of the Warrant Shares, the Warrant Shares issued pursuant to any such exercise shall be issued
free of all legends. If at any time following the date hereof any required registration statement registering the sale or resale
of the Warrant Shares is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company
shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter
shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of
the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or
any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company
shall use best efforts to keep a registration statement registering the issuance or resale of the Warrant Shares effective during
the term of the Warrants.


 


4.2
Transfer Restrictions.


 


(a)
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of
Securities other than pursuant to an effective registration statement or Rule 144, to the Company or in connection with a pledge
as contemplated in Section 4.2(b) or a transfer to an Affiliate of the Purchaser, the Company may require the transferor thereof
to provide to the Company at the Company’s expense, an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any
such transferee shall agree in writing to be bound by the terms of this Agreement, including the representations and warranties
made by the Purchaser herein, and shall have the rights of a Purchaser under this Agreement.


 




    	23



    	 



    

 


(b)
The Purchaser agrees to the imprinting by the Company, so long as is required by this Section 4.2, of a legend on any of the Securities
in substantially the following form:


 


[NEITHER]
THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT,
AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [CONVERSION]
OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.


 


The
Company acknowledges and agrees that the Purchaser may from time to time grant a security interest in some or all of the Securities
to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and
who agrees in writing with the Company to be bound by the provisions of this Agreement and, if required under the terms of such
arrangement and subject to compliance with applicable federal and state securities laws, the Purchaser may transfer secured Securities
to the secured parties. Absent special circumstances, such a transfer would not be subject to approval of the Company and no legal
opinion of legal counsel of the secured party shall be required in connection therewith. At the Purchaser’s expense, the
Company will execute and deliver such reasonable documentation as a secured party of Securities may reasonably request in connection
with a pledge or transfer of the Securities.


 


(c)
The Company agrees that certificates evidencing the Conversion Shares and the Warrant Shares (or, if Conversion Shares or Warrant
Shares are issued in uncertificated form, comparable share notices) shall not contain any legend (including the legend set forth
in Section 4.2(b) hereof) (“Unlegended Shares”): (i) while a registration statement covering the resale of
such security is effective under the Securities Act, or (ii) following any sale of such Conversion Shares or Warrant Shares pursuant
to Rule 144, or (iii) if such Conversion Shares or Warrant Shares are eligible for sale under Rule 144, without the requirement
for the Company to be in compliance with the current public information required under Rule 144 as to such Conversion Shares or
Warrant Shares and without volume or manner-of-sale restrictions, or (iv) if such legend is not otherwise required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission),
as reasonably determined by the Company. Upon the Purchaser’s request in connection with a proposed sale of Conversion Shares
or Warrant Shares pursuant to Rule 144 and if the Company reasonably determines it is so required, upon receipt of customary documentation
from Purchaser’s broker (if the Conversion Shares or Warrant Shares are sold in brokers transactions), the Company shall,
at its own cost and effort, retain legal counsel to provide an opinion letter to the Company’s transfer agent opining that
the Conversion Shares or Warrant Shares may be resold without registration under the Securities Act, pursuant to Rule 144, promulgated
thereunder, so long as the requirements of Rule 144 are met for any Conversion Shares or Warrant Shares to be resold thereunder.
The Company shall arrange for any such opinion letter to be provided not later than two (2) business days after the date of delivery
to and receipt by the Company of a written request by the Purchaser together with (if required in order to render the opinion)
any broker’s representation letter of other customary documentation reasonably requested by the Company evidencing compliance
with Rule 144 (the “Legend Removal Date”).


 




    	24



    	 



    

 


(d)
The Purchaser agrees that the Purchaser will sell any Securities only pursuant to either an exemption from registration or a registration
statement under the Securities Act, including any applicable prospectus delivery requirements, and that if Securities are sold
pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges
that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.2 is predicated
upon the Company’s reliance upon this understanding.


 


(e)
Legend Removal Default. In addition to such Purchaser’s other available remedies, provided the conditions for legend
removal set forth in Section 4.2(c) exist, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not
as a penalty, for each One Thousand Dollars ($1,000.00) of Conversion Shares and/or Warrant Shares (based on the higher of the
actual purchase price or VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for
removal of the restrictive legend and subject to Section 4.2(d), Ten Dollars ($10.00) per Trading Day for each Trading Day after
the Legend Removal Date (increasing to Twenty Dollars ($20.00) per Trading Day after the third Trading Day) until such certificate
is delivered without a legend. Nothing herein shall limit such Purchaser’s right to pursue actual damages for the Company’s
failure to deliver certificates representing any Securities as required by the Transaction Documents, and such Purchaser shall
have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief.


 


(f)
DWAC. In lieu of delivering physical certificates representing the Unlegended Shares, upon request of a Purchaser, so long
as the certificates therefor do not bear a legend and the Purchaser is not obligated to return such certificate for the placement
of a legend thereon, the Company shall cause its transfer agent to electronically transmit the Unlegended Shares by crediting
the account of Purchaser’s prime broker with the Depository Trust Company through its Deposit Withdrawal At Custodian system,
provided that the Company’s Common Stock is DTC eligible and the Company’s transfer agent participates in the Deposit
Withdrawal at Custodian system. Such delivery must be made on or before the Legend Removal Date.


 




    	25



    	 



    

 


(g)
Injunction. In the event a Purchaser shall request delivery of Unlegended Shares as described in this Section 4.2 and the
Company is required to deliver such Unlegended Shares, the Company may not refuse to deliver Unlegended Shares based on any claim
that such Purchaser or anyone associated or affiliated with such Purchaser has not complied with Purchaser’s obligations
under the Transaction Documents, or for any other reason, unless, an injunction or temporary restraining order from a court, on
notice, restraining and or enjoining delivery of such Unlegended Shares shall have been sought and obtained by the Company and
the Company has posted a surety bond for the benefit of such Purchaser in the amount of the greater of (i) one hundred twenty
percent (120%) of the amount of the aggregate purchase price of the Conversion Shares or Warrant Shares to be subject to the injunction
or temporary restraining order, or (ii) the VWAP of the Common Stock on the trading day before the issue date of the injunction
multiplied by the number of Unlegended Shares to be subject to the injunction, which bond shall remain in effect until the completion
of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Purchaser to the extent Purchaser
obtains judgment in Purchaser’s favor.


 


(h)
Buy-In. In addition to any other rights available to Purchaser, if the Company fails to deliver to a Purchaser Unlegended
Shares as required pursuant to this Agreement and after the Legend Removal Date the Purchaser, or a broker on the Purchaser’s
behalf, purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by
such Purchaser of the shares of Common Stock which the Purchaser was entitled to receive in unlegended form from the Company (a
“Buy-In”), then the Company shall promptly pay in cash to the Purchaser (in addition to any remedies available
to or elected by the Purchaser) the amount, if any, by which (A) the Purchaser’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (B) the aggregate purchase price of the shares of Common
Stock delivered to the Company for reissuance as Unlegended Shares together with interest thereon at a rate of fifteen percent
(15%) per annum accruing until such amount and any accrued interest thereon is paid in full (which amount shall be paid as liquidated
damages and not as a penalty). For example, if a Purchaser purchases shares of Common Stock having a total purchase price of Eleven
Thousand Dollars ($11,000.00) to cover a Buy-In with respect to Ten Thousand Dollars ($10,000.00) of purchase price of Conversion
Shares or Warrant Shares delivered to the Company for reissuance as Unlegended Shares, the Company shall be required to pay the
Purchaser One Thousand Dollars ($1,000.00), plus interest, if any. The Purchaser shall provide the Company written notice indicating
the amounts payable to the Purchaser in respect of the Buy-In.


 


(i)
Plan of Distribution. Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that
such Purchaser will sell any Securities pursuant to either the registration requirements of the Securities Act, including any
applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a registration
statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal
of the restrictive legend from certificates representing Securities as set forth in this Section 4.2 is predicated upon the Company’s
reliance upon this understanding.


 




    	26



    	 



    

 


4.3
Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the
outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges
that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Conversion Shares
and Warrant Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off,
counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against the
Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the
Company.


 


4.4
Consent of Holders. From the Initial Closing Date until twelve (12) months after the Initial Closing Date , so long as
any portion of the Note has not been converted into Conversion Shares,, the Company shall, in the event of an offer or sale of
the New Securities, (a) notify the Purchaser in writing of the detailed terms and conditions of such offer or sale of the New
Securities at least five (5) days prior to the estimated issue date of such New Securities, and (b) obtain the prior written consent
of the Purchaser on such offer or sale of the New Securities This Section 4.4 shall terminate at the time the Common Stock of
the Company is listed on a national securities exchange.


 


4.5
Furnishing of Information.


 


(a)
Until the earlier to occur of the time that (i) the Purchaser owns no Securities, or (ii) the Warrants have expired, the Company
covenants that it will maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to use
all commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace
period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. As long as the Purchaser
owns Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the
Purchaser and make publicly available in accordance with Rule 144(c) such information as is required for the Purchaser to sell
the Securities under Rule 144. The Company further covenants that it will use all commercially reasonable efforts to take such
further action as any holder of Securities may reasonably request, to the extent required from time to time to enable such Person
to sell such Securities without registration under the Securities Act within the requirements of the exemption provided by Rule
144.


 


(b)
At any time commencing on the Closing Date and ending at such time that all of the Securities may be sold without the requirement
for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144,
if the Company shall fail for any reason to satisfy the current public information requirement under Rule 144(c) (a “Public
Information Failure”) then, in addition to such Purchaser’s other available remedies, the Company shall pay to
a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or impairment of its
ability to sell the Securities, an amount in cash equal to two percent (2.0%) of the aggregate principal amount of the Note and
accrued interest thereon, held by such Purchaser on the day of a Public Information Failure and on every thirtieth (30th) day
(pro-rated for periods totaling less than thirty (30) days) thereafter until the earlier of (a) the date such Public Information
Failure is cured and (b) such time that such public information is no longer required for the Purchasers to transfer the Conversion
Shares or Warrant Shares pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section 4.5(b)
are referred to herein as “Public Information Failure Payments.” Public Information Failure Payments shall
be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred
and (ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured.
In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure
Payments shall bear interest at the rate of one and one-half percent (1.5%) per month (prorated for partial months) until paid
in full. Nothing herein shall limit such Purchaser’s right to pursue actual damages for the Public Information Failure,
and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief.


 




    	27



    	 



    

 


4.6
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in
a manner that would require the registration under the Securities Act of the sale of the Securities or that would be integrated
with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require
shareholder approval prior to the closing of such other transaction or to effectuate such other transaction unless shareholder
approval is obtained before the earlier of the closing of such subsequent transaction or effectuation of such other transaction.


 


4.7
Conversion and Exercise Procedures. Each of the form of Notice of Conversion included in the Note and the form of Notice
of Exercise included in the Warrants sets forth the totality of the procedures required of the Purchaser in order to convert the
Note or exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchaser
to convert their Note or exercise their Warrants. The Company shall honor conversions of the Note and exercises of the Warrants
and shall deliver Conversion Shares and Warrant Shares, respectively, in accordance with the terms, conditions and time periods
set forth in the Transaction Documents.


 


4.8
Securities Laws Disclosure; Publicity. Immediately following each Closing Date, but in no event later than 4:00 PM (New
York City time) on the next Trading Day, the Company shall file a Current Report on Form 8-K, disclosing the material terms of
the transactions contemplated hereby with respect to the applicable Securities and including the Transaction Documents as exhibits
thereto. From and after the filing of the Form 8-K, the Company represents to the Purchasers that the Company shall have publicly
disclosed all material, non-public information delivered to Purchaser by the Company or any of its Subsidiaries, or any of their
respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents
with respect to the applicable Securities. The Company and the Purchaser shall consult with each other in issuing any other press
releases with respect to the transactions contemplated hereby, and neither the Company nor the Purchaser shall issue any such
press release nor otherwise make any such public statement (other than in the Company’s SEC Reports after the initial Closing
Date or exhibits filed therewith) without the prior consent of the Company, with respect to any press release of the Purchaser,
or without the prior consent of the Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide
the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, other than in connection
with the Company’s SEC Reports or disclosures to any regulatory agency or Trading Market that the Company determines are
necessary or appropriate, the Company shall not publicly disclose the name of the Purchaser, or include the name of the Purchaser,
in any press release or similar public statement, without the prior written consent of the Purchaser.


 




    	28



    	 



    

 


4.9
Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, that the Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect, or that the
Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the
Transaction Documents or any other agreement between the Company and the Purchaser.


 


4.10
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, the Company covenants and agrees that after the Closing Date neither it, nor any other Person acting on
its behalf, will provide the Purchaser or its agents or counsel with any information that the Company believes constitutes material
non-public information, unless prior thereto the Purchaser shall have executed a written agreement regarding the confidentiality
and use of such information. The Company understands and confirms that the Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company. Purchaser acknowledges that it is aware that the United States securities
laws prohibit any person who has material non-public information about a company from purchasing or selling securities of such
company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable
that such person is likely to purchase or sell such securities, and Purchaser agrees not to engage in any unlawful trading in
securities of the Company or unlawful misuse or misappropriation of any such information. Purchaser agrees to maintain the confidentiality
of and not disclose or use (except for purposes relating to the transactions contemplated by this Agreement) any confidential,
proprietary or non-public information disclosed by the Company to Purchaser, unless such information becomes publicly known through
no breach of this Agreement by Purchaser.


 


4.11
Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for repayment of debt
and working capital purposes.


 




    	29



    	 



    

 


4.12
Indemnification of Purchaser. Subject to the provisions of this Section 4.12, the Company will indemnify and hold the Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
the Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title) of such controlling person and their respective
heirs, personal representatives, successors and assigns (each, a “Purchaser Party”) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer
or incur as a result of or relating to any action, suit, claim or proceeding brought by a third party against such Purchaser Party
arising out of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against a Purchaser in any capacity, or any
of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of the Purchaser, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser’s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings the Purchaser may
have with any such stockholder or any violations by the Purchaser of state or federal securities laws or any conduct by the Purchaser
which constitutes fraud, gross negligence, willful misconduct or malfeasance, as determined by a final judgment of a court of
competent jurisdiction from which no appeal may be taken). If any action shall be brought against the Purchaser Party in respect
of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing,
and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the
Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after
a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion
of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such
Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser
Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z)
to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach
of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents, as determined by a final judgment of a court of competent jurisdiction from which no appeal may be taken.


 


4.13
Reservation and Listing of Securities.


 


(a)
The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction
Documents in such amount as may then be required to fulfill its obligations in full under the Transaction Documents. Upon request
by a Purchaser, the Company shall deliver, or cause the Transfer Agent to deliver, to each Purchaser a statement of number of
shares of Common Stock that are currently reserved for issuance pursuant to the Transaction Documents. On the Closing Date, the
Company shall authorize the Transfer Agent that, at any time while the Note or any Warrants remain outstanding, upon delivery
by a Purchaser to the Transfer Agent of a notice to increase the number of shares of Common Stock that are reserved for issuance
pursuant to the Transaction Documents, the Transfer Agent shall promptly increase the reserved amount of shares of Common Stock
and provide confirmation in writing thereof to the Purchaser.


 




    	30



    	 



    

 


(b)
If, on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than the Required
Minimum on such date, then the Board of Directors shall use commercially reasonable efforts to amend the Company’s certificate
or articles of incorporation to increase the number of authorized but unissued shares of Common Stock to at least the Required
Minimum at such time, as soon as possible and in any event not later than the seventy fifth (75th) calendar day after
such date.


 


(c)
The Company shall, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and file with such
Trading Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required
Minimum on the date of such application, (ii) take all steps necessary to cause such shares of Common Stock to be approved for
listing or quotation on such Trading Market as soon as possible thereafter, (iii) provide to the Purchaser evidence of such listing
and (iv) maintain the listing of such Common Stock on any date at least equal to the Required Minimum on such date on such Trading
Market or another Trading Market.


 


4.14
Subsequent Equity Sales.


 


(a)
From the date hereof until one hundred eighty (180) days after the Closing Date, neither the Company nor any Subsidiary shall
issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common
Stock Equivalents, except in connection with the Provista acquisition. This Section 4.14(a) shall no longer be in effect if the
closing sale price of the Company’s Common Stock exceeds $0.10 at any time. For the avoidance of doubt, under no circumstance
shall the Company issue or agree to issue shares for consideration of an amount less than $0.10, and in no event shall the price
for any issued shares be reset to a price less than $0.10.


 


(b)
From the date hereof until such time that Purchaser no longer holds the Note or Warrant, the Company shall be prohibited from
effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common
Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. “Variable Rate Transaction”
means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable
or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise
price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares
of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or
exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or
upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market
for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity
line of credit or an at-the-market facility whereby the Company may issue securities at a future determined price. Purchaser Any
Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall
be in addition to any right to collect damages.


 




    	31



    	 



    

 


(c)
Notwithstanding the foregoing, the prohibitions set forth in this Section 4.14 shall not apply solely with respect to transactions
between the Company and Yozma Global Genomic Fund 1 or its Affiliates (collectively, “Yozma”); provided that
any such transactions contain substantially the same terms as those set forth in that certain Securities Purchase Agreement between
the Company and Yozma, dated as of January 22, 2021, and the ancillary documents, instruments and agreements relating thereto.


 


(d)
If the Company enters into or effects a Variable Rate Transaction in violation of the prohibition set forth in Section 4.14(b)
herein, the Company shall pay to each Purchaser, in cash, as liquidated damages and not as a penalty, an amount equal to Two Hundred
Fifty Thousand Dollars ($250,000). For purposes of clarity, the Company shall pay the liquidated damages described herein for
each Variable Rate Transaction that violates the prohibition set forth in Section 4.14(b) herein. The Company shall pay to Purchaser
such amount of liquidated damages in cash by wire transfer within three (3) Trading Days of the date of such Variable Rate Transaction.
Nothing herein shall limit Purchaser’s right to pursue actual damages for the Company’s violation of the prohibition
in Section 4.14(b), and Purchaser shall have the right to pursue all remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief.


 


(e)
Notwithstanding the foregoing, this Section 4.14 shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance.


 


(f)
So long as any Note is outstanding, the Company may not incur any indebtedness of any sort, other than trade payables and purchase-money
financing.


 


4.15
Corporate Existence. So long as any Note remains outstanding, the Company shall not directly or indirectly consummate any
merger, reorganization, restructuring, consolidation, sale of all or substantially all of the Company’s assets or any similar
transaction or related transactions (each such transaction, an “Organizational Change”) unless, prior to the
consummation an Organizational Change, the Company obtains the written consent of the Purchaser, which consent shall not be unreasonably
withheld. In any such case, the Company will make appropriate provision with respect to such holders’ rights and interests
to insure that the provisions of this Section 4.15 will thereafter be applicable to the Note.


 


4.16
Transfer Agent. The Company covenants and agrees that it will at all times while the Note remains outstanding maintain
a duly qualified independent transfer agent.


 


4.17
No Short Selling. The Purchaser has and shall not, directly or indirectly, his, her or itself, through related parties,
affiliates or otherwise, (i) sell “short” or “short against the box” (as those terms are generally understood)
any equity security of the Company or (ii) otherwise engage in any transaction that involves hedging of the Purchaser’s
position in any equity security of the Company, until the later of (i) the date the Note owned by the Purchaser is no longer owned
by the Purchaser, or (ii) the Maturity Date (as such term is defined in the Note) and the Conversion Date (as such term is defined
in the Note).


 




    	32



    	 



    

 


4.18
DTC Program. At all times that the Note is outstanding, the Company shall employ as the transfer agent for its Common Stock,
Conversion Shares and Warrant Shares a participant in the Depository Trust Company Automated Securities Transfer Program and cause
the Common Stock, Conversion Shares and Warrant Shares to be transferable pursuant to such program.


 


4.19
Reverse Stock Split. The Company will consummate a reverse stock split (the ratio of which shall be 1:10 or such other
ratio as agreed upon by the Company and the Purchaser) of its ordinary shares within one hundred twenty (120) days of the Initial
Closing Date.


 


4.20
Participation Rights. From the Initial Closing Date until the date when the Purchaser no longer holds any of the Note,
Conversion Shares, Warrant or Warrant Shares, the Purchaser shall have the right to participate in up to a maximum of one hundred
percent (100%) of any transaction the Company contemplates conducting pursuant to Section 3(a)(9) of the Securities Act of 1933
(the “Transaction”). Upon the Company becoming aware of a Transaction, the Company shall provide notice of
such Transaction (“3(a)(9) Notice”) and its terms to the Purchaser and the Purchaser shall have seventy two (72) hours
from receipt of the 3(a)(9) Notice (“Notice Termination Time”) to indicate to the Company that they want to
participate and the amount of such participation or they decline to participate. If Purchaser does not respond by the Notice Termination
Time, the Company may conduct the Transaction without the Purchaser’s participation.


 


4.21.
Uplisting. Prior to the Initial Closing Date, the Purchaser shall have the option of investing any portion of the Second
Subscription Amount into an uplisting transaction for the Company. In the event of an uplisting of the Company’s Common
Stock, Section 4.20 shall terminate.


 


ARTICLE
V 


MISCELLANEOUS


 


5.1
Termination. This Agreement may be terminated by the Purchaser, as to the Purchaser’s obligations hereunder only
and without any effect whatsoever on the obligations between the Company and the Purchaser, by written notice to the Company,
if the Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; provided,
however, that such termination will not affect the right of any party to sue for any breach by the other party (or parties).


 


5.2
Fees and Expenses. Except as set forth on Schedule 3.1(t) or except as expressly set forth in the Transaction Documents
to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and
all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this
Agreement. At each Closing, the Company shall pay to Purchaser a Due Diligence and Legal Expenses Fee of Sixty-Two Thousand Five
Hundred Dollars ($62,500.00). The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in
connection with the delivery of any Securities to the Purchaser.


 


5.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.


 




    	33



    	 



    

 


5.4
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party
shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder
shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting
facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where
such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during
normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by
express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur. The addresses for such communications shall be: (i) if to the Company, to: Todos Medical Ltd., 1 Hamada Street, Rehovot,
Israel, and (ii) if to the Purchaser, to: ________.


 


5.5
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or
a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any
right hereunder in any manner impair the exercise of any such right.


 


5.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.


 


5.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Purchaser (other than by merger). The Purchaser may assign any or all of its rights under this Agreement to any
Person to whom the Purchaser assigns or transfers any Securities, provided that such transfer complies with all applicable federal
and state securities laws and that such transferee agrees in writing with the Company to be bound, with respect to the transferred
Securities, by the provisions of the Transaction Documents that apply to the Purchaser.


 


5.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as
otherwise set forth in Section 4.12.


 




    	34



    	 



    

 


5.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to
the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any action, suit or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section 4.12, the prevailing party in such action, suit or proceeding shall be reimbursed by
the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.


 


5.10
Survival. The representations and warranties shall survive the Closing and the delivery of the Securities until, with respect
to the Purchaser, the Note held by the Purchaser has been paid in full or converted into Conversion Shares, and no Warrants are
held by the Purchaser, at which time they shall expire such respect to Purchaser and shall no longer be of any force or effect.


 


5.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as
if such facsimile or “.pdf” signature page were an original thereof.


 


5.12
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.


 




    	35



    	 



    

 


5.13
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever the Purchaser exercises a right, election, demand or option under
a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then
the Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant
notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however,
that in the case of a rescission of a conversion of the Note or exercise of a Warrant, the Purchaser shall be required to return
any shares of Common Stock subject to any such rescinded conversion or exercise notice.


 


5.14
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances
shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement
Securities.


 


5.15
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchaser and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained
in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.


 


5.16
Payment Set Aside. To the extent that the Company makes a payment or payments to the Purchaser pursuant to any Transaction
Document or the Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered
from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other
person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of
action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.


 




    	36



    	 



    

 


5.17
Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now
or at any time hereafter in force, in connection with any claim, action or proceeding that may be brought by the Purchaser in
order to enforce any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in
any Transaction Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents
for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of
them, when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction
Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to
the Transaction Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof,
the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from
the effective date forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest
in excess of the Maximum Rate is paid by the Company to the Purchaser with respect to indebtedness evidenced by the Transaction
Documents, such excess shall be applied by the Purchaser to the unpaid principal balance of any such indebtedness or be refunded
to the Company, the manner of handling such excess to be at the Purchaser’s election.


 


5.18
Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under
the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated
damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial
liquidated damages or other amounts are due and payable shall have been canceled.


 


5.19
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.


 


5.20
Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be
resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
hereto.


 


5.21
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.


 


(Signature
Pages Follow)


 




    	37



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.


 


	TODOS
    MEDICAL LTD.  	 	Address
    for Notice:
	 	 	 
	By:	/s/	 	Fax:	 
	Name:
    	 	 	 	 
	Title:
    	 	 	 	 
	 	 	 	 	 
	With
    a copy to (which shall not constitute notice):	 	 	 


 


Solely
for purposes of Section 4.21:


 


____________________________


Gerald
Commissiong


 


[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK


 


SIGNATURE
PAGE FOR PURCHASER FOLLOWS]


 




    	 



    	 



    

 


PURCHASER
SIGNATURE PAGES TO TODOS MEDICAL LTD. SECURITIES PURCHASE AGREEMENT


 


IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.


 


Name
of Purchaser:


 


Signature
of Authorized Signatory of Purchaser: _______________________________________


 


Name
of Authorized Signatory:


 


Title
of Authorized Signatory:


 


	 	 	Initial Closing	 	 	Second Closing	 
	Subscription Amount	 	$	4,285,714.29	 	 	$	5,285,714.29	 
	Principal Amount of Note	 	$	4,285,714.29	 	 	$	5,285,714.29	 
	Warrant Shares	 	 	16,000,000	 	 	 	16,000,000	 
	 	 	 	 	 	 	 	 	 
	Aggregate
    Subscription Amount:	 	 	$
                                            9,571,428.57	 



 




    	 



    	 



    

 


Annex
A


 


CLOSING
STATEMENT


 


Todos
Medical Ltd., a corporation organized and existing under the laws of Israel (the “Company”) hereby delivers
this Closing Statement on [______ __], 20[__], in connection to the attached Securities Purchase Agreement, dated as of April
8, 2021 (the “Purchase Agreement”). Capitalized terms used but not defined herein have the meaning set forth
in the Purchase Agreement. Pursuant to this [Initial / Second] Closing, _______ (“Purchaser”) shall purchase
[_______] Dollars ($[_______]) of securities from the Company. All funds will be wired into an account maintained by the Company
and disbursed in accordance with this Closing Statement.


 


[By
signing below, the undersigned duly authorized officer of the Company hereby certifies the following on behalf of the Company
as of the Second Closing Date:


 


	 	a)	the
    representations and warranties of the Company with respect to the Second Securities are accurate in all respects (as determined
    without regard to any materiality, Material Adverse Effect or other similar qualifiers therein); 
	 	 	 
	 	b)	the
    Company has performed all obligations, covenants and agreements required to be performed by the Company with respect to the
    Second Securities; 
	 	 	 
	 	c)	the
    Company has delivered each item set forth in Section 2.2(c) of the Purchase Agreement; and
	 	 	 
	 	d)	No
    Material Adverse Effect has occurred with respect to the Company since the Effective Date.]1


 


Disbursement
Date:_________, 2021


 


 






 


	I. [INITIAL / SECOND] SUBSCRIPTION PRICE
	 	$	 [4,285,714.29] / [5,285,714.29]	 
	Total Proceeds from Offering	 	$	[3,000,000.00]
/ [3,700,000.00]	 
	 	 	 	 	 
	II. DISBURSEMENTS
	 	 	 	 
	 Purchaser Legal and Due Diligence Fees	 	$	62,500.00	 
	 	 	$		 
	 	 	$		 
	 	 	 	 	 
	Total Amount Disbursed:	 	$	[______]	 



 


WIRE INSTRUCTIONS: Please see attached.



 


[Signature Page Follows]


 


 




1 NTD – Applicable to
Second Closing Only.


 






    	 	 	 



     


    

 


Acknowledged
and agreed to this [___] day of[ _________], 202[_].


 


	COMPANY:
	 
	TODOS
    MEDICAL LTD.
	 
	By:
    	 	 
	Name:	 	 
	Title:	 	 


 


[Signature
Page to Closing Statement]


 




    	 



    	 



    

 


Exhibit
A


 


Form
of Note


 




    	Exhibit A - 1



    	 



    

 


Exhibit
B


 


Form
of Warrant


 




    	Exhibit B - 1